Our findings implied that immunosuppression, rather than angiogenesis, in the breast cancer microenvironment is the crucial mechanism conferring resistance to anti-VEGFR2 therapy exerted by γδT cells and neutrophils. The gene discussed is KDR; the disease is breast cancer.